- Home
- FCEL vs PROK Comparison
FCEL vs PROK Comparison
Compare FCEL & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FCEL
- PROK
- Stock Information
- Founded
- FCEL 1969
- PROK 2015
- Country
- FCEL United States
- PROK United States
- Employees
- FCEL N/A
- PROK N/A
- Industry
- FCEL Industrial Machinery/Components
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FCEL Energy
- PROK Health Care
- Exchange
- FCEL Nasdaq
- PROK Nasdaq
- Market Cap
- FCEL 144.6M
- PROK 126.8M
- IPO Year
- FCEL 1992
- PROK N/A
- Fundamental
- Price
- FCEL $4.62
- PROK $0.84
- Analyst Decision
- FCEL Hold
- PROK Buy
- Analyst Count
- FCEL 6
- PROK 4
- Target Price
- FCEL $14.28
- PROK $5.00
- AVG Volume (30 Days)
- FCEL 715.9K
- PROK 434.6K
- Earning Date
- FCEL 03-11-2025
- PROK 05-09-2025
- Dividend Yield
- FCEL N/A
- PROK N/A
- EPS Growth
- FCEL N/A
- PROK N/A
- EPS
- FCEL N/A
- PROK N/A
- Revenue
- FCEL $114,438,000.00
- PROK $76,000.00
- Revenue This Year
- FCEL $42.70
- PROK N/A
- Revenue Next Year
- FCEL $13.23
- PROK N/A
- P/E Ratio
- FCEL N/A
- PROK N/A
- Revenue Growth
- FCEL 11.09
- PROK N/A
- 52 Week Low
- FCEL $4.36
- PROK $0.80
- 52 Week High
- FCEL $37.20
- PROK $4.44
- Technical
- Relative Strength Index (RSI)
- FCEL 29.07
- PROK 29.40
- Support Level
- FCEL $4.36
- PROK $0.87
- Resistance Level
- FCEL $4.99
- PROK $1.00
- Average True Range (ATR)
- FCEL 0.31
- PROK 0.10
- MACD
- FCEL -0.02
- PROK 0.01
- Stochastic Oscillator
- FCEL 11.56
- PROK 14.70
About FCEL FuelCell Energy Inc.
FuelCell Energy Inc is a fuel-cell power company. FuelCell designs manufactures, sells, installs, operates, and services fuel cell products and electrolysis platforms that decarbonize power and produce hydrogen. It serves various industries such as Industrial, Wastewater treatment, Commercial and Hospitality, Data centers and Communications, Education and Healthcare, and others. Geographically, the company generates a majority of its revenue from the United States followed by South Korea.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease.